AIDX.US 20/20 Biolabs, Inc. Common Stock
- Market cap
- USD 2.73M
- P/E
- -
- P/B
- 1.68x
- ROE
- -233.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is AIDX.US undervalued?
Graham numberThe Graham number of 20/20 Biolabs, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
20/20 Biolabs, Inc. Common Stock fundamental analysis
No fundamental analysis for 20/20 Biolabs, Inc. Common Stock yet.
20/20 Biolabs, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About 20/20 Biolabs, Inc. Common Stock
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. a…
Full company profile20/20 Biolabs, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
20/20 Biolabs, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 427K | 313K | 277K | 288K | 2.33M | 9.62M | 11.1M | 1.42M | 1.75M | 2.05M | 2.17M |
| Gross Profit | 171K | 131K | 59.5K | 24.4K | 877K | 4.69M | 5.12M | 109K | 360K | 605K | 735K |
| Operating Income | -2.23M | -1.28M | -1.47M | -2.47M | -2.03M | 1.94M | 1.68M | -6.36M | -5.66M | -3.33M | -5.38M |
| EBITDA | -2.21M | -1.27M | -1.44M | -2.42M | -1.97M | 2.07M | 1.97M | -6.19M | -5.53M | -3.50M | -6.24M |
| Net Income | -2.23M | -1.26M | -1.46M | -2.43M | -2.02M | 2.07M | 2.19M | -6.39M | -5.55M | -3.74M | -7.36M |
| EPS | -0.48 | -0.27 | -0.31 | -0.51 | -0.43 | 0.22 | 0.23 | -1.34 | -1.16 | -0.60 | -0.68 |
| Balance Sheet | |||||||||||
| Total Assets | 1.35M | 1.42M | 4.11M | 3.13M | 4.68M | 10.3M | 12.2M | 6.37M | 3.61M | 4.14M | 6.12M |
| Total Liabilities | 562K | 966K | 821K | 977K | 1.29M | 3.38M | 2.84M | 2.08M | 2.08M | 4.16M | 2.96M |
| Shareholders' Equity | 784K | 456K | 3.28M | 2.15M | 3.39M | 6.89M | 9.37M | 4.29M | 1.53M | -19.2K | 3.16M |
| Cash & Short-term Investments | 982K | 1.04M | 3.27M | 2.28M | 3.47M | 3.35M | 8.81M | 4.09M | 1.78M | 1.03B | 4.55M |
| Total Debt | - | - | - | - | 144K | 2.35M | 2.41M | 2.07M | 1.51M | 1.28B | 572K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.89M | -1.06M | -1.31M | -2.12M | -2.04M | -1.07M | 5.80M | -4.63M | -2.60M | -1.92M | -3.79M |
| Capital Expenditure | 0.00 | 5.00 | 64.1K | 2.29K | 184K | 228K | 262K | 9.38K | 5.00 | 0.00 | 21.4K |
| Free Cash Flow | -1.89M | -1.06M | -1.38M | -2.13M | -2.22M | -1.30M | 5.54M | -4.64M | -2.60M | -1.92M | -3.78M |
| Ratios | |||||||||||
| ROE | -284.1% | -277.1% | -44.5% | -112.8% | -59.7% | 30.1% | 23.3% | -149.1% | -361.9% | - | -233.0% |
| ROA | -165.5% | -88.9% | -35.6% | -77.6% | -43.2% | 20.2% | 17.9% | -100.4% | -153.7% | -90.4% | -120.2% |
| Net Profit Margin | -521.8% | -403.6% | -528.1% | -841.3% | -86.8% | 21.5% | 19.8% | -448.7% | -316.8% | -182.8% | -339.6% |
| Debt to Equity | - | - | - | - | 0.04x | 0.34x | 0.26x | 0.48x | 0.99x | - | 0.18x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
20/20 Biolabs, Inc. Common Stock dividends
20/20 Biolabs, Inc. Common Stock has not paid dividends in the last 9 fiscal years.
Who owns 20/20 Biolabs, Inc. Common Stock
- Insiders 15.56%
- Institutions 3.57%
- Public & others 80.87%
- Shares outstanding 13.4M
- Free float 10.8M
Top funds holding AIDX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 43.6K | 0.33% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 5.32K | 0.04% | 0.00% | Aug 2026 |
Top institutions holding AIDX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Cresset Asset Management, LLC | 240K | 1.96% | -9.17% | Jun 2026 |
| HRT FINANCIAL LLC | 89.3K | 0.73% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 52.1K | 0.43% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 49.1K | 0.40% | 0.00% | Jun 2026 |
| Atlantic Union Bankshares Corp | 35.1K | 0.29% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 24.5K | 0.20% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 23.2K | 0.19% | +43.00% | Jun 2026 |
| Bank of America Corp | 13.0K | 0.11% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 10.0K | 0.08% | 0.00% | Jun 2026 |
| McDonald Partners, LLC | 2.80K | 0.02% | 0.00% | Jun 2026 |
| SignatureFD, LLC | 767.00 | 0.01% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 283.00 | 0.00% | 0.00% | Jun 2026 |
| Hanson Mcclain Inc | 172.00 | 0.00% | +473.33% | Jun 2026 |
| Toth Financial Advisory Corp | 100.00 | 0.00% | -36.31% | Jun 2026 |
| UBS Group AG | 3.00 | 0.00% | -99.96% | Jun 2026 |
| Mccormack Advisors International | 0.00 | 0.00% | -100.00% | Jun 2026 |
| XTX Topco Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
20/20 Biolabs, Inc. Common Stock company profile
- Company name
- 20/20 Biolabs, Inc. Common Stock
- Ticker
- AIDX.US
- Exchange
- USA Stocks
- Listed since
- Feb 19, 2026
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 4
- Fiscal year end
- December
- Address
- 15810 Gaither Road, Gaithersburg, MD, United States, 20877
- Phone
- 240 453 6339
- Website
- 2020biolabs.com
About 20/20 Biolabs, Inc. Common Stock
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
20/20 Biolabs, Inc. Common Stock management
7- Mr. Jonathan CohenFounder, CEO, President & Director · born 1964
- Dr. Jiming Zhou Ph.D.Chief Operating Officer · born 1968
- Dr. Michael Saul Lebowitz Ph.D.Chief Scientific Officer · born 1969
- Mr. Alan B. BergmanChief Financial Officer · born 1969
- Mr. David LeesDirector of Sales
- Mr. Ronald R. BakerChief Business Officer · born 1951
- Marc GordonController